Pfizer’s financial centre in Prague celebrates the first anniversary of its establishment and plans further growth

14 Oct. 2015 | CzechInvest | The American ambassador to the Czech Republic, Andrew Schapiro, took part in the celebration.

Finanční centrum Pfizer v Praze slaví rok od založení a plánuje další růst

Today the American company Pfizer celebrated the passage of a year since the opening of its Global Financial Solution Centre in Prague. The company invested more than CZK 180 million in the centre, where it currently employs 45 financial and accounting experts who provide services for five countries, namely the Czech Republic, Russia, Hungary, Poland and Greece.

Pfizer has only five such centres throughout the world. The Prague centre is the first in Central and Eastern Europe. “Investors from the United States do not have specific knowledge of the Czech Republic in a number of cases. An exception is technological fields, where the Czech Republic has a long history and good reputation,” said Karel Kučera, CEO of CzechInvest. “There are ideal conditions here for shared-services centres, which is perfectly illustrated by Pfizer’s successful year in Prague.”

The celebration of the centre’s first anniversary on Wednesday, 14 October 2015, in Prague’s Smíchov district was attended by the US ambassador to the Czech Republic, Andrew Schapiro. During the event, KyRic Tucker, director of Pfizer’s Global Financial Solution Centre in Prague, outlined the company’s future plans for the centre. “By 2018, we want to expand the centre’s support to four more countries and we are also considering a possible expansion to other European countries in the future,” Tucker said.

With more than 97,000 employees worldwide, Pfizer Inc. is a leading global biopharmaceutical company founded on research and development of proprietary drugs. The company, which has been based in New York since its establishment in 1849, conducts research, development and sales of human medications, including biological pharmaceuticals. Pfizer also performs clinical trials of new drugs, including in the Czech Republic, where it has been operating since 1993.